資源描述：
《漢灘病毒多組分新型重組腺病毒的制備及免疫學特性研究》由會員上傳分享，免費在線閱讀，更多相關內(nèi)容在學術論文-天天文庫。
1、獨創(chuàng)性聲明秉承學校嚴謹?shù)膶W風與優(yōu)良的科學道德，本人聲明所呈交的論文是我個人在導師指導下進行的研究工作及取得的研究成果。盡我所知，除了文中特別加以標注和致謝的地方外，論文中不包含其他人已經(jīng)發(fā)表或撰寫過的研究成果，不包含本人或他人已申請學位或其他用途使用過的成果。與我一同工作的同志對本研究所做的任何貢獻均已在論文中作了明確的說明并表示了致謝。申請學位論文與資料若有不實之處，本人承擔一切相關責任。論文作者簽名：日期：保護知識產(chǎn)權聲明本人完全了解第四軍醫(yī)大學有關保護知識產(chǎn)權的規(guī)定，即：研究生在校攻讀學位期間論
2、文工作的知識產(chǎn)權單位為第四軍醫(yī)大學。本人保證畢業(yè)離校后，發(fā)表論文等使用本論文工作成果時第一署名單位仍然為第四軍醫(yī)大學。學?？梢怨颊撐牡娜炕虿糠謨?nèi)容（含電子版，保密內(nèi)容除外），可以采用影印，縮印或其他復制手段保存論文；學校有權允許論文被查閱和借閱，并在校園網(wǎng)上提供論文內(nèi)容的瀏覽和下載服務。同意學校將論文加入《中國優(yōu)秀博碩士學位論文全文數(shù)據(jù)庫》和編入《中國知識資源總庫》等，并可瀏覽和下載，同時享受《中國優(yōu)秀博碩士學位論文全文數(shù)據(jù)庫出版章程》規(guī)定的相關權益。論文作者簽名：導師簽名：日期：博士學位論文目錄
3、縮略語表···································································································································1中文摘要·················································································································
4、··················4ABSTRACT·····························································································································9前言··································································································
5、·······························15文獻回顧·································································································································18正文···················································································
6、··············································30第一部分····································································································································30含漢灘病毒結構基因雙順反子及HSP70C的重組腺病毒的制備及免疫學特性研究··301材料·······················
7、································································································301.1菌種、質粒載體、引物及病毒株··································································301.2動物及細胞······························································
8、········································311.3工具酶··············································································································311.4抗體及HFRS患者血清·······················································
